Stemline Therapeutics Company Profile (NASDAQ:STML)

About Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:STML
  • CUSIP: N/A
  • Web: www.stemline.com
Capitalization:
  • Market Cap: $272.5 million
  • Outstanding Shares: 23,455,000
Average Prices:
  • 50 Day Moving Avg: $10.90
  • 200 Day Moving Avg: $9.16
  • 52 Week Range: $5.50 - $14.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.54
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.2 million
  • Price / Sales: 216.96
  • Book Value: $3.41 per share
  • Price / Book: 3.26
Profitability:
  • EBITDA: ($49,340,000.00)
  • Net Margins: -4,176.84%
  • Return on Equity: -67.35%
  • Return on Assets: -58.14%
Debt:
  • Current Ratio: 4.65%
  • Quick Ratio: 4.65%
Misc:
  • Average Volume: 183,803 shs.
  • Beta: -0.12
  • Short Ratio: 12.07
 

Frequently Asked Questions for Stemline Therapeutics (NASDAQ:STML)

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics, Inc. (NASDAQ:STML) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.66) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.18. The business earned $0.30 million during the quarter, compared to analysts' expectations of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. View Stemline Therapeutics' Earnings History.

When will Stemline Therapeutics make its next earnings announcement?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Stemline Therapeutics.

Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2017?

6 brokers have issued 1-year price targets for Stemline Therapeutics' stock. Their predictions range from $16.00 to $41.00. On average, they anticipate Stemline Therapeutics' stock price to reach $32.60 in the next twelve months. View Analyst Ratings for Stemline Therapeutics.

What are analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:

  • 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (7/18/2017)
  • 2. HC Wainwright analysts commented, "Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year." (5/15/2017)
  • 3. Cowen and Company analysts commented, "STML reported 1Q17 financials and provided a pipeline update." (5/12/2017)

Who are some of Stemline Therapeutics' key competitors?

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the folowing people:

  • Ivan Bergstein M.D., Chairman of the Board, President, Chief Executive Officer
  • Kenneth Hoberman, Chief Operating Officer
  • David G. Gionco, Chief Accounting Officer, Vice President - Finance
  • Ron Bentsur, Independent Director
  • J. Kevin Buchi, Independent Director
  • Eric L. Dobmeier, Independent Director
  • Alan S. Forman, Independent Director
  • Kenneth J. Zuerblis, Independent Director

How do I buy Stemline Therapeutics stock?

Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of Stemline Therapeutics stock can currently be purchased for approximately $11.10.


MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.60 (193.69% upside)
Consensus Price Target History for Stemline Therapeutics (NASDAQ:STML)
Price Target History for Stemline Therapeutics (NASDAQ:STML)
Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017HC WainwrightReiterated RatingBuy$34.00MediumView Rating Details
6/14/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
5/25/2017Jefferies Group LLCReiterated RatingBuy$16.00MediumView Rating Details
5/11/2017WedbushBoost Price TargetOutperform$33.00 -> $40.00HighView Rating Details
3/20/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$41.00MediumView Rating Details
12/7/2016Roth CapitalReiterated RatingBuy$32.00N/AView Rating Details
3/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Stemline Therapeutics (NASDAQ:STML)
Earnings by Quarter for Stemline Therapeutics (NASDAQ:STML)
Earnings History by Quarter for Stemline Therapeutics (NASDAQ STML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.61)N/AView Earnings Details
8/8/2017Q2 2017($0.48)($0.66)$0.30 million$0.30 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.45)($0.67)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)$0.15 million$0.21 millionViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)$0.10 million$0.21 millionViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)$0.10 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q1($0.45)($0.46)$0.09 million$0.12 millionViewN/AView Earnings Details
3/13/2015($0.60)($0.53)$0.07 million$0.12 millionViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)$0.07 million$0.07 millionViewN/AView Earnings Details
8/14/2014($0.71)($0.47)$0.07 million$0.07 millionViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)
2017 EPS Consensus Estimate: ($2.19)
2018 EPS Consensus Estimate: ($2.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.68)($0.68)($0.68)
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.54)($0.54)($0.54)
Q3 20181($0.55)($0.55)($0.55)
Q4 20181($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Stemline Therapeutics (NASDAQ:STML)
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 48.42%
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/28/2017David GioncoInsiderSell6,486$6.99$45,337.14View SEC Filing  
2/28/2017Ivan BergsteinCEOSell17,980$6.99$125,680.20View SEC Filing  
2/28/2017Kenneth HobermanCOOSell8,027$6.99$56,108.73View SEC Filing  
2/27/2017David GioncoCAOSell3,500$6.97$24,395.00View SEC Filing  
2/27/2017Ivan BergsteinCEOSell7,500$6.97$52,275.00View SEC Filing  
2/27/2017Kenneth HobermanCOOSell4,000$6.97$27,880.00View SEC Filing  
2/16/2017Ivan BergsteinCEOSell3,652$6.42$23,445.84View SEC Filing  
2/16/2017Kenneth HobermanCOOSell1,508$6.42$9,681.36View SEC Filing  
1/19/2017David GioncoInsiderSell3,593$11.46$41,175.78View SEC Filing  
1/10/2017Kenneth HobermanCOOSell9,110$13.82$125,900.20View SEC Filing  
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.58View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.94View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.00View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Stemline Therapeutics (NASDAQ:STML)
Latest Headlines for Stemline Therapeutics (NASDAQ:STML)
Source:
DateHeadline
americanbankingnews.com logoStemline Therapeutics, Inc. (STML) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 4:46 AM
thestreet.com logoStemline Therapeutics Stock Sees Short Interest Drop 17%
www.thestreet.com - October 11 at 3:29 PM
prnewswire.com logoBiotech's Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)
www.prnewswire.com - September 20 at 9:37 AM
prnewswire.com logoBiotech's Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)
www.prnewswire.com - September 20 at 9:37 AM
globenewswire.com logoStemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
www.globenewswire.com - September 20 at 9:37 AM
globenewswire.com logoStemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
www.globenewswire.com - September 20 at 9:37 AM
finance.yahoo.com logoStemline Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 20 at 9:37 AM
finance.yahoo.com logoStemline Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 20 at 9:37 AM
americanbankingnews.com logoStemline Therapeutics, Inc. (STML) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 17 at 4:40 AM
americanbankingnews.com logoStemline Therapeutics, Inc. (STML) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 12 at 9:24 AM
finance.yahoo.com logoStemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
finance.yahoo.com - September 11 at 7:15 AM
finance.yahoo.com logoStemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 8 at 8:50 AM
finance.yahoo.com logoETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 9:12 AM
feeds.benzinga.com logoStemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
feeds.benzinga.com - August 30 at 8:19 PM
finance.yahoo.com logoStemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 1:27 PM
americanbankingnews.com logoStemline Therapeutics, Inc. (STML) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 23 at 4:44 AM
finance.yahoo.com logoStemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 15 at 7:25 AM
americanbankingnews.com logoStemline Therapeutics, Inc. (NASDAQ:STML) Expected to Post Q3 2017 Earnings of ($0.62) Per Share
www.americanbankingnews.com - August 14 at 2:06 AM
globenewswire.com logoStemline Therapeutics Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 10 at 8:19 AM
americanbankingnews.com logoStemline Therapeutics Inc (NASDAQ:STML) Announces Earnings Results, Misses Expectations By $0.18 EPS
www.americanbankingnews.com - August 9 at 3:48 PM
finance.yahoo.com logoStemline Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 7:54 AM
finance.yahoo.com logoStemline Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 7:11 AM
americanbankingnews.com logoStemline Therapeutics, Inc. (NASDAQ:STML) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 29 at 7:45 AM
americanbankingnews.com logoStemline Therapeutics, Inc. (NASDAQ:STML) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 4 at 11:28 AM
streetinsider.com logoStemline Therapeutics (STML) Announces SL-401 Updated Stage 1 & 2 Data from Ongoing Pivotal Trial in BPDCN ... - StreetInsider.com
www.streetinsider.com - June 25 at 6:43 AM
feeds.benzinga.com logoStemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA
feeds.benzinga.com - June 23 at 10:17 AM
globenewswire.com logoStemline Therapeutics to Present at the Jefferies 2017 Healthcare ... - GlobeNewswire (press release)
globenewswire.com - June 6 at 11:18 PM
feeds.benzinga.com logoStemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference
feeds.benzinga.com - June 6 at 7:46 AM
streetinsider.com logoStemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHA
www.streetinsider.com - May 19 at 12:51 PM
streetinsider.com logoStemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 ... - StreetInsider.com
www.streetinsider.com - May 18 at 12:55 PM
globenewswire.com logoStemline Therapeutics Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 1:19 AM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Novan, Stemline Therapeutics, BioDelivery Sciences, and ... - PR Newswire (press release)
www.prnewswire.com - April 25 at 9:35 AM
globenewswire.com logoUPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM
globenewswire.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM
us.rd.yahoo.com logoDeadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc.
us.rd.yahoo.com - March 31 at 1:30 AM
feeds.benzinga.com logoAPRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - March 30 at 10:06 PM
streetinsider.com logoStemline Therapeutics (STML) Completes Enrollment in Stage 3 of ... - StreetInsider.com
www.streetinsider.com - March 25 at 5:40 AM
biz.yahoo.com logoSTEMLINE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
us.rd.yahoo.com - March 24 at 7:55 PM
us.rd.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
us.rd.yahoo.com - March 24 at 7:55 PM
us.rd.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 24 at 7:55 PM
streetinsider.com logoStemline Therapeutics (STML) Completes Enrollment in Stage 3 of SL-401 Pivotal Trial in BPDCN
www.streetinsider.com - March 24 at 1:44 AM
biz.yahoo.com logoSTEMLINE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - March 17 at 8:04 PM
us.rd.yahoo.com logoShareholder Deadline Reminder (STML): Johnson & Weaver, LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 17 at 8:04 PM
us.rd.yahoo.com logoSHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 17 at 8:04 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Stemline Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
us.rd.yahoo.com - March 17 at 8:04 PM
feeds.benzinga.com logoStemline Investors Reminder: Hagens Berman Reminds Investors in Stemline Therapeutics of the April 4, 2017 Lead Plaintiff Deadline
feeds.benzinga.com - March 17 at 4:40 PM
biz.yahoo.com logoSTEMLINE THERAPEUTICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 8:49 PM
us.rd.yahoo.com logoIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 13 at 7:41 PM
benzinga.com logoSTEMLINE SHAREHOLDER ALERT BY FORMER LOUISIANA...
www.benzinga.com - March 11 at 7:59 PM
prnewswire.com logoSTEMLINE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC ... - PR Newswire (press release)
www.prnewswire.com - March 11 at 5:10 AM

Social

Chart

Stemline Therapeutics (STML) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.